336 results on '"Hidetaka Katabuchi"'
Search Results
2. Progressive idiopathic juvenile osteoporosis in pregnancy: A case report of two successive pregnancies in the same woman
- Author
-
Kaori Kishimoto, Chisato Kodera, Fumitaka Saito, Takashi Ohba, and Hidetaka Katabuchi
- Subjects
Juvenile osteoporosis ,Bisphosphonate ,Osteoporosis ,Lactation ,Pregnancy ,Delivery ,Surgery ,RD1-811 ,Gynecology and obstetrics ,RG1-991 - Abstract
A 33-year-old primiparous woman with progressive idiopathic juvenile osteoporosis (IJO) who had had multiple vertebral compressions and bilateral femoral neck fractures since the age of 15 years presented for perinatal management at 11 weeks of gestation. Her vertebral bone mass was 0.634 g/cm2 before pregnancy. The target calcium intake was set at 800 mg/day. Cephalopelvic disproportion led to the patient having an elective cesarean section at 39 weeks 3 days of gestation and she delivered a female infant weighing 2785 g. After the delivery, her vertebral bone mass had increased to 0.700 g/cm2. At 34 years of age, she conceived her second child. With similar perinatal management, she delivered a female infant weighing 2580 g at 38 weeks of gestation by elective cesarean section. Her vertebral bone mass had increased again after the second pregnancy. Few cases of pregnancy complicated by progressive IJO have been reported. However, an uneventful pregnancy course can be expected with proper management, and pregnancy can be a good opportunity to increase bone mass.
- Published
- 2021
- Full Text
- View/download PDF
3. Analysis of pathological and clinical characteristics of cervical conization according to age group in Japan
- Author
-
Isao Murakami, Akiko Ohno, Masae Ikeda, Hiroshi Yamashita, Mikio Mikami, Yoichi Kobayashi, Satoru Nagase, Masatoshi Yokoyama, Takayuki Enomoto, and Hidetaka Katabuchi
- Subjects
Cancer research ,Cancer surgery ,Gynecology ,Oncology ,Clinical research ,Cervical intraepithelial neoplasia ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Objective: With increased screening, more patients with precancerous or early cervical cancer are now being identified. Age at pregnancy, and thus number of patients requiring fertility preservation, have also increased, resulting in more diagnostic and therapeutic cervical conization (conization) procedures. We here investigated the pathological and clinical characteristics of patients undergoing conization, with a focus on age. The objectives of our study were to identify the risk factors potentially involved in cervical intraepithelial neoplasia (CIN) recurrence or persistence, additional treatment after conization, the effects of conization on pregnancy, and the actual status of conization in Japan. Study design: A “Subcommittee for Investigation of Cervical Conization” within the Gynecologic Oncology Committee in the Japan Society of Obstetrics and Gynecology investigated pathological and clinical characteristics of conization at 205 institutions in Japan. We analyzed pathological and clinical characteristics according to age ≤50 and >50 years. Results: Patients aged 20–40 years accounted for 12904 (87%) of the 14,832 study patients (median: 37 years, range: 16–88 years). However, 1838 (12.4%) were aged >50 years. The commonest post-operative diagnosis was CIN grade 3 in all age groups. Rates of invasive cancer, post-operative detection of more advanced lesions, positive surgical margins, additional treatment, and recurrence were significantly higher in patients aged ≥50 years than those aged
- Published
- 2020
- Full Text
- View/download PDF
4. The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report
- Author
-
Tatsuya Kondo, Miwa Nakamura, Sayaka Kitano, Junji Kawashima, Takeshi Matsumura, Takashi Ohba, Munekage Yamaguchi, Hidetaka Katabuchi, and Eiichi Araki
- Subjects
Gestational diabetes insipidus ,Vasopressinase (=insulin regulated aminopeptidase: IRAP) ,Glucose transporter 4 ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Gestational diabetes insipidus (GDI) is a rare endocrine complication during pregnancy that is associated with vasopressinase overproduction from the placenta. Although increased vasopressinase is associated with placental volume, the regulation of placental growth in the later stage of pregnancy is not well known. Case presentation A 16-year-old pregnant woman was urgently transferred to our hospital because of threatened premature labor when the Kumamoto earthquakes hit the area where she lived. During her hospitalization, she complained of gradually increasing symptoms of polyuria and polydipsia. The serum level of arginine vasopressin (AVP) was 1.7 pg/mL, which is inconsistent with central DI. The challenge of diagnostic treatment using oral 1-deamino-8-D-AVP (DDAVP) successfully controlled her urine and allowed for normal delivery. DDAVP tablets were not necessary to control her polyuria thereafter. Based on these observations, clinical diagnosis of GDI was confirmed. Pathophysiological analyses revealed that vasopressinase expression was more abundant in the GDI patient’s syncytiotrophoblast in placenta compared with that in a control subject. Serum vasopressinase was also observed during gestation and disappeared soon after delivery. Vasopressinase is reportedly identical to oxytocinase or insulin regulated aminopeptidase (IRAP), which is an abundant cargo protein associated with the glucose transporter 4 (GLUT4) storage vesicle. Interestingly, the expression and subcellular localization of GLUT4 appeared to occur in a vasopressinase (IRAP)-dependent manner. Conclusion Because placental volume may be associated with vasopressinase overproduction in GDI, vasopressinase (IRAP)/GLUT4 association appears to contribute to the growth of placenta in this case.
- Published
- 2018
- Full Text
- View/download PDF
5. Preoperative Diagnosis of Intestinal Endometriosis by Magnifying Colonoscopy and Target Biopsy
- Author
-
Jun Tomiguchi, Hideaki Miyamoto, Kazutaka Ozono, Ryosuke Gushima, Takashi Shono, Hideaki Naoe, Motohiko Tanaka, Hideo Baba, Hidetaka Katabuchi, and Yutaka Sasaki
- Subjects
Endometriosis ,Magnifying endoscopy ,Target biopsy ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Endometriosis can affect any portion of the gastrointestinal tract. A preoperative definitive diagnosis of intestinal endometriosis is difficult, because there is no characteristic endoscopic finding and the endoscopic biopsies usually sample insufficient endometrial tissue for pathologic diagnosis. To our knowledge, the magnifying endoscopic features of intestinal mucosal endometriosis have not been well documented. In this study, we report a case of intestinal endometriosis diagnosed preoperatively by magnifying image-enhanced colonoscopy and target biopsy. A 45-year-old woman was referred to our hospital with abdominal pain in the left lower quadrant. Colonoscopy showed a submucosal tumor-like lesion of approximately 30 mm in diameter exhibiting surface reddening and granular changes in the sigmoid colon. Magnifying endoscopy revealed sparsely distributed round pits in the granules. The mucosal biopsy specimen from the granule provided the diagnosis of intestinal endometriosis. Segmental sigmoidectomy was performed, and pathological examination revealed that the surface colonic mucosa was partially replaced by endometrial tissue, which accounted for the granular change detected in the colonoscopy. It can be speculated that the round pit might reflect the endometrial glands surrounded by endometrial stroma. This case illustrated the characteristic finding and utility of magnifying endoscopy for mucosal intestinal endometriosis.
- Published
- 2017
- Full Text
- View/download PDF
6. Sac-Type Congenital Diaphragmatic Hernia: A Case Report of Two Siblings
- Author
-
Chisato Kodera, Takashi Ohba, Tomomi Hashimoto, Munekage Yamaguchi, Hidetaka Yoshimatsu, and Hidetaka Katabuchi
- Subjects
Gynecology and obstetrics ,RG1-991 - Abstract
Congenital diaphragmatic hernia (CDH), a herniation of the abdominal contents through a defect or hypoplasia of the diaphragm, is a relatively common, severe congenital anomaly. Here we present the first case of two siblings with possibly isolated sac-type CDH and with a suspected genetic etiology. Although sibling recurrence of isolated CDH is rare, the incidence is higher than in the general population. Additionally, the second child had a more severe respiratory disorder than the first child. It is to be noted that siblings of children having isolated CDH are at risk for CDH, and prenatal evaluation should be considered individually.
- Published
- 2018
- Full Text
- View/download PDF
7. Choriocarcinoma coexisting with epithelioid trophoblastic tumor of the uterine horn
- Author
-
Yuko Imamura, Hironori Tashiro, Fumitaka Saito, Kiyomi Takaishi, Takashi Ohba, Masaharu Fukunaga, and Hidetaka Katabuchi
- Subjects
Gestational trophoblastic neoplasia ,Choriocarcinoma ,Epithelioid trophoblastic tumor ,Trophoblastic stem cell ,Chemotherapy ,Uterine horn ,Gynecology and obstetrics ,RG1-991 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2015
- Full Text
- View/download PDF
8. Pancreatic Metastasis from Mixed Adenoneuroendocrine Carcinoma of the Uterine Cervix: A Case Report
- Author
-
Chihiro Nishimura, Hideaki Naoe, Shunpei Hashigo, Hideharu Tsutsumi, Shotaro Ishii, Takeyasu Konoe, Takehisa Watanabe, Takashi Shono, Kouichi Sakurai, Kiyomi Takaishi, Yoshiaki Ikuta, Akira Chikamoto, Motohiko Tanaka, Ken-ichi Iyama, Hideo Baba, Hidetaka Katabuchi, and Yutaka Sasaki
- Subjects
Pancreatic metastasis ,Uterine cervical mixed adenoneuroendocrine carcinoma ,Middle pancreatectomy ,Endoscopic ultrasonography-guided fine needle aspiration ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Metastatic cancers of the pancreas are rare, accounting for approximately 2-4% of all pancreatic malignancies. Renal cell carcinoma is the most common solid tumor that metastasizes to the pancreas. Here, we present a case of uterine cervical carcinoma metastasizing to the pancreas and review the literature regarding this rare event. A 44-year-old woman with a uterine cervical tumor had undergone radical hysterectomy and had been diagnosed pathologically with stage Ib mixed adenoneuroendocrine carcinoma in 2004. She underwent concurrent radiotherapy and chemotherapy postoperatively. Pulmonary metastases subsequently appeared in 2008 and 2011, and she underwent complete resection of the lung tumors by video-assisted thoracic surgery. Although she was followed up without any treatment and with no other recurrences, positron emission tomography revealed an area of abnormal uptake within the pancreatic body in 2012. Enhanced computed tomography demonstrated a 20-mm lesion in the pancreatic body and upstream pancreatic duct dilatation. Endoscopic ultrasonography-guided fine needle aspiration was performed and pathological examination suggested neuroendocrine carcinoma (NEC). On the basis of these results and the patient's oncological background, lesions in the pancreatic body were diagnosed as secondary metastasis from the cervical carcinoma that had been treated 8 years earlier. No other distant metastases were visualized, and the patient subsequently underwent middle pancreatectomy. Pathological examination showed NEC consistent with pancreatic metastasis from the uterine cervical carcinoma. The patient has survived 7 months since the middle pancreatectomy without any signs of local recurrence or other metastatic lesions.
- Published
- 2013
- Full Text
- View/download PDF
9. Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations
- Author
-
Navneet Sangha, Rong Wu, Rork Kuick, Scott Powers, David Mu, Diane Fiander, Kit Yuen, Hidetaka Katabuchi, Hironori Tashiro, Eric R. Fearon, and Kathleen R. Cho
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Ovarian serous carcinoma (OSC) is the most common and lethal histologic type of ovarian epithelial malignancy. Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified. Using a genome-wide screen of DNA copy number alterations in 36 primary OSCs, we identified two tumors with apparent homozygous deletions of the NF1 gene. Subsequently, 18 ovarian carcinoma-derived cell lines and 41 primary OSCs were evaluated for NF1 alterations. Markedly reduced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression. Similarly, NF1 alterations including homozygous deletions and splicing mutations were identified in 9 (22%) of 41 primary OSCs. As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines). The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
- Published
- 2008
- Full Text
- View/download PDF
10. Spontaneous Rupture of an Unscarred Gravid Uterus in a Primigravid Woman at 32 Weeks of Gestation
- Author
-
Etsuko Mizutamari, Tomoko Honda, Takashi Ohba, and Hidetaka Katabuchi
- Subjects
Gynecology and obstetrics ,RG1-991 - Abstract
Uterine rupture usually occurs in a scarred uterus, especially secondary to prior cesarean section. Antepartum uterine rupture in an unscarred uterus is extremely rare. We report a case of spontaneous rupture of an unscarred gravid uterus at 32 weeks of gestation in a primigravid woman. Ultrasonography and magnetic resonance imaging showed a bulging cystic lesion communicating with the intrauterine cavity. Operative findings during emergent cesarean section revealed uterine perforation in the right cornual area and a prolapsed, nonbleeding amniotic sac. The left cornual area was also focally thin. An arcuate uterus was suspected based on follow-up hysterosalpingography. Antepartum uterine rupture tends to occur in the uterine cornual area. In this case, Müllerian duct anomalies may have been associated with focal myometrial defects.
- Published
- 2014
- Full Text
- View/download PDF
11. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
- Author
-
Kosuke Yoshihara, Atsushi Tajima, Tetsuro Yahata, Shoji Kodama, Hiroyuki Fujiwara, Mitsuaki Suzuki, Yoshitaka Onishi, Masayuki Hatae, Kazunobu Sueyoshi, Hisaya Fujiwara, Yoshiki Kudo, Kohei Kotera, Hideaki Masuzaki, Hironori Tashiro, Hidetaka Katabuchi, Ituro Inoue, and Kenichi Tanaka
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer. METHODOLOGY/PRINCIPAL FINDINGS: Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p
- Published
- 2010
- Full Text
- View/download PDF
12. Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan.
- Author
-
Hiroko Machida, Koji Matsuo, Takahiro Higashi, Daisuke Aoki, Takayuki Enomoto, Aikou Okamoto, Hidetaka Katabuchi, Satoru Nagase, Masaki Mandai, Nobuo Yaegashi, Wataru Yamagami, and Mikio Mikami
- Subjects
HEALTH facilities ,QUALITY-adjusted life years ,ENDOMETRIAL cancer ,SURVIVAL rate ,CANCER hospitals - Abstract
Objective: Hospital treatment volume affects survival in patients with endometrial cancer; notably, initial treatment at high-volume centers improves survival outcomes. Our study assessed the effect of hospital treatment volume on cost-effectiveness and survival outcomes in patients with endometrial cancer in Japan. Methods: A decision-analytic model was evaluated using the following variables and their impact on cost-effectiveness: 1) hospital treatment volume (low-, intermediate-, and high-volume centers) and 2) postoperative recurrent risk factors based on pathological findings (high- and intermediate-risk or low-risk). Data were obtained from the Japan Society of Obstetrics and Gynecology database, systematic literature searches, and the Japanese Diagnosis Procedure Combination database. Quality-adjusted life years (QALY) was used as a measure of effectiveness. The model was built from a public healthcare perspective and the impact of uncertainty was assessed using sensitivity analyses. Results: A base-case analysis showed that the incremental cost-effectiveness ratio at high-volume centers was below a willingness-to-pay (WTP) threshold of ¥5,000,000 with a maximum of ¥3,777,830/4.28 QALY for the high- and intermediate-risk group, and ¥2,316,695/4.57 QALY for the low-risk group. Treatment at the high-volume centers showed better efficiency and cost-effectiveness in both strategies compared to intermediate- or low-volume centers. Sensitivity analyses showed that the model outcome was robust to changes in input values. With the WTP threshold, treatment at high-volume centers remained cost-effective in at least 73.6% and 78.2% of iterations for high- and intermediate-risk, and low-risk groups, respectively. Conclusion: Treatment at high-volume centers is the most cost-effective strategy for guiding treatment centralization in patients with endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. A critical review of 'uterine leiomyoma' with subsequent recurrence or metastasis: A multicenter study of 62 cases
- Author
-
Sakiko Sanada, Kimio Ushijima, Hiroyuki Yanai, Yoshiki Mikami, Yoshihiro Ohishi, Hiroaki Kobayashi, Hironori Tashiro, Mikio Mikami, Shingo Miyamoto, and Hidetaka Katabuchi
- Subjects
Leiomyosarcoma ,Leiomyomatosis ,Uterine Neoplasms ,Humans ,Mesenchymoma ,Multicenter Studies as Topic ,Obstetrics and Gynecology ,Female ,Smooth Muscle Tumor - Abstract
Histopathologic diagnosis of a subset of uterine smooth muscle tumors is challenging. We report a critical review regarding the clinicopathological point of view of 62 cases of subsequently recurred or metastasized leiomyoma.Medical records and glass slides of 62 cases of uterine smooth muscle tumor diagnosed as leiomyoma, which subsequently recurred or metastasized, were critically reviewed by pathologists specializing in gynecologic pathology and oncology.In 47 (75.8%) of 62 cases, the diagnosis of leiomyoma was confirmed, including 11 intravascular leiomyomatosis (IVL) and benign metastasizing leiomyoma (BML). In 29 cases (46.8%) laparoscopic surgery was performed, of which morcellator without a bag was employed in 23 cases. Fifteen cases (24.2%) appeared to be underestimated and were re-classified as smooth muscle tumor of uncertain malignant potential (STUMP), leiomyosarcoma, or other malignant mesenchymal tumors. Recurrences in seven cases (11.3%) were interpreted to be a malignant transformation, and one STUMP recurred as STUMP.The recurrence or metastasis in cases of "leiomyoma" is attributed to iatrogenic or under-evaluation of primary tumors, although a subset of cases is a rare example of biological progression.
- Published
- 2022
14. Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment.
- Author
-
Manabu Seino, Satoru Nagase, Hideki Tokunaga, Wataru Yamagami, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kaneuchi, Yasuyuki Hirashima, Hitoshi Niikura, Kiyoshi Yoshino, Kazuhiro Takehara, Tsukasa Baba, Hidetaka Katabuchi, and Mikio Mikami
- Subjects
GYNECOLOGIC oncology ,CERVICAL cancer ,MEDICAL personnel ,MERKEL cell carcinoma ,NEUROENDOCRINE tumors ,MINIMALLY invasive procedures - Abstract
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cervical cancer, indicate appropriate current treatment methods for cervical cancer, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden of patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO Guideline Committee, based on a careful review of evidence gathered through the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise seven chapters and 5 algorithms. The main features of the 2022 revision are as follows: 1) added discussed points at the final consensus meeting; 2) revised the treatment methods based on the International Federation of Gynecology and Obstetrics 2018 staging system; 3) examined minimally invasive surgery based on Laparoscopic Approach to Cervical Cancer trial; 4) added clinical question (CQ) for treatments of rare histological types, gastric type, and small-cell neuroendocrine carcinoma; 5) added CQ for intensity-modulated radiation therapy; 6) added CQ for cancer genomic profiling test; and 7) added CQ for cancer survivorship. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2022 for the Treatment of Uterine Cervical Cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Impact of Estrogen Replacement Therapy on Hypogonadal Survivors of Childhood Cancer
- Author
-
Miwa Nakamura, Takashi Ohba, Rumi Sasaki, Fumitaka Saito, Munekage Yamaguchi, Takeshi Motohara, Hiroyo Mabe, Xi Lu, Hidetaka Katabuchi, and Eiji Kondoh
- Abstract
Background: Hypogonadism is a significant late complication in childhood cancer survivors (CCS). The aim of this study was to elucidate the benefits and limitations of estrogen replacement therapy (ERT) for CCS with hypogonadism. Methods: Seventeen CCS were divided into two groups: gonadal hypogonadism (GH) group (n=8) and central hypogonadism (CH) group (n=9). Pearson correlation coefficients were used to investigate the impact of cancer management on final height, bone density, and uterine development. Results: Seven of GH group had hematologic malignancies, and all of them underwent total body irradiation before bone marrow transplantation. The GH group showed significant positive correlations between the onset age of disease treatment and final height (p < 0.05, R = 0.712) and uterine size following ERT (p < 0.05, R = 0.775). All CCS in the CH group had brain tumors, and seven of them received chemotherapy. There were trends towards positive and negative correlations between the onset age of disease treatment and final height (p = 0.09, R = 0.527) or uterine size (p = 0.07, R = -0.669), respectively. A negative correlation trend was observed between the age at ERT initiation and final height (p = 0.07, R = -0.769) or bone density (p = 0.18, R = -0.626) in six CH patients who received growth hormone therapy. Five CCS in both groups experienced osteoporosis, despite receiving ERT. Conclusion: Individualized management strategies beyond ERT are essential to reduce long-term complications in CCSs with hypogonadism, considering the type and timing of cancer treatment.
- Published
- 2023
16. Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis
- Author
-
Tatsuyuki Chiyoda, Kosuke Yoshihara, Masahiro Kagabu, Satoru Nagase, Hidetaka Katabuchi, Mikio Mikami, Tsutomu Tabata, Yasuyuki Hirashima, Yoichi Kobayashi, Masanori Kaneuchi, Hideki Tokunaga, and Tsukasa Baba
- Subjects
Indocyanine Green ,Oncology ,Sentinel Lymph Node Biopsy ,Humans ,Uterine Cervical Neoplasms ,Female ,Surgery ,Hematology ,General Medicine ,Sentinel Lymph Node ,Coloring Agents ,Retrospective Studies - Abstract
Sentinel node navigation surgery (SNNS) is used in clinical practice for the treatment of cervical cancer. This study aimed to elucidate the appropriate sentinel lymph node (SLN) mapping method and assess the safety and benefits of SNNS. We searched the PubMed, Ichushi, and Cochrane Library databases for randomized controlled trials (RCT) and studies on SLN in cervical cancer from January 2012 to December 2020. Two authors independently assessed study quality and extracted data. We quantitatively analyzed the detection rate, sensitivity/specificity, and complications and reviewed information, including the survival data of SLN biopsy (SLNB) without pelvic lymphadenectomy (PLND). The detection rate of SLN mapping in the unilateral pelvis was median 95.7% and 100% and in the bilateral pelvis was median 80.4% and 90% for technetium-99 m (Tc) with/without blue dye (Tc w/wo BD) and indocyanine green (ICG) alone, respectively. The sensitivity and specificity of each tracer were high; the area under the curve of each tracer was 0.988 (Tc w/wo BD), 0.931 (BD w/wo Tc), 0.966 (ICG), and 0.977 (carbon nanoparticle). Morbidities including lymphedema, neurological symptoms and blood loss were associated with PLND. One RCT and five studies all showed SNNS without systematic PLND does not impair recurrence or survival in early-stage cervical cancer with a tumor size ≤ 2-4 cm. Both Tc w/wo BD and ICG are appropriate SLN tracers. SNNS can reduce the morbidities associated with PLND without affecting disease progression in early-stage cervical cancer.
- Published
- 2022
17. Supplementary Table 2 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 292K
- Published
- 2023
18. Supplementary Table 3 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 302K
- Published
- 2023
19. Supplementary Table 1 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 484K
- Published
- 2023
20. Supplementary Figure 4 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 133K
- Published
- 2023
21. Data from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
Purpose: High-grade serous ovarian cancers are heterogeneous not only in terms of clinical outcome but also at the molecular level. Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients.Experimental Design: In this large-scale cross-platform study of six microarray data sets consisting of 1,054 ovarian cancer patients, we developed a gene expression signature for predicting overall survival by applying elastic net and 10-fold cross-validation to a Japanese data set A (n = 260) and evaluated the signature in five other data sets. Subsequently, we investigated differences in the biological characteristics between high- and low-risk ovarian cancer groups.Results: An elastic net analysis identified a 126-gene expression signature for predicting overall survival in patients with ovarian cancer using the Japanese data set A (multivariate analysis, P = 4 × 10−20). We validated its predictive ability with five other data sets using multivariate analysis (Tothill's data set, P = 1 × 10−5; Bonome's data set, P = 0.0033; Dressman's data set, P = 0.0016; TCGA data set, P = 0.0027; Japanese data set B, P = 0.021). Through gene ontology and pathway analyses, we identified a significant reduction in expression of immune-response–related genes, especially on the antigen presentation pathway, in high-risk ovarian cancer patients.Conclusions: This risk classification based on the 126-gene expression signature is an accurate predictor of clinical outcome in patients with advanced stage high-grade serous ovarian cancer and has the potential to develop new therapeutic strategies for high-grade serous ovarian cancer patients. Clin Cancer Res; 18(5); 1374–85. ©2012 AACR.
- Published
- 2023
22. Supplementary Table 6 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 338K
- Published
- 2023
23. Supplementary Figure 1 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 163K
- Published
- 2023
24. Supplementary Materials and Methods from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 81K
- Published
- 2023
25. Supplementary Table 4 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 586K
- Published
- 2023
26. Supplementary Figure 5 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 190K
- Published
- 2023
27. Supplementary Table 5 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 648K
- Published
- 2023
28. Supplementary Figure 2 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 213K
- Published
- 2023
29. Supplementary Figure 8 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 232K
- Published
- 2023
30. Supplementary Figure 7 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 435K
- Published
- 2023
31. Supplementary Figure 3 from High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway
- Author
-
Kenichi Tanaka, Ituro Inoue, Atsushi Tajima, Takuya Moriya, Hitoshi Tsuda, Kohei Akazawa, Mikio Mikami, Takayuki Enomoto, Yasuhisa Terao, Hiroyuki Seki, Haruko Iwase, Kimio Ushijima, Tamotsu Sudo, Etsuko Miyagi, Masashi Takano, Hiroaki Itamochi, Tsuyoshi Saito, Yasuhiro Udagawa, Noriomi Matsumura, Takayoshi Nogawa, Aikou Okamoto, Yosuke Kawakami, Hidetaka Katabuchi, Hideaki Masuzaki, Hisaya Fujiwara, Masayuki Hatae, Hiroyuki Fujiwara, Daichi Shigemizu, Tatsuhiko Tsunoda, and Kosuke Yoshihara
- Abstract
PDF file - 168K
- Published
- 2023
32. Perinatal manifestation of pseudohypoaldosteronism type 2 in a mother and her children
- Author
-
Takashige Kuwabara, Chisato Kodera, Takashi Ohba, and Hidetaka Katabuchi
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Medicine ,Pseudohypoaldosteronism Type 2 ,business - Published
- 2021
33. Surgical efficacy and quality of wide resection of the pelvic peritoneum in patients with epithelial ovarian cancer
- Author
-
Akiho Nishimura, Takeshi Motohara, Jun Morinaga, Yutaka Iwagoi, Mayuko Yamamoto, Munekage Yamaguchi, Yo Miyahara, Hironori Tashiro, and Hidetaka Katabuchi
- Subjects
Oncology ,Surgery - Abstract
Purpose The aim of study was to evaluate the impact of adding an extensive pelvic peritoneal stripping procedure, termed “wide resection of the pelvic peritoneum,” (WRPP) to standard surgery for epithelial ovarian cancer on survival effectiveness and to investigate the role of ovarian cancer stem cells (CSCs) in the pelvic peritoneum. Methods A total of 166 patients with ovarian cancer undergoing surgical treatment at Kumamoto University Hospital between 2002 and 2018 were retrospectively analyzed. Eligible patients were divided into three groups based on the surgical approach: standard surgery (SS) group (n = 36), WRPP group (standard surgery plus WRPP, n = 100), and rectosigmoidectomy (RS) group (standard surgery plus RS, n = 30). Survival outcomes were compared between the three groups. CD44 variant 6 (CD44v6) and EpCAM expression, as markers of ovarian CSCs, in peritoneal disseminated tumors were evaluated using immunofluorescence staining. Results With respect to patients with stage III–IV ovarian cancer, there were significant differences in overall and progression-free survival between the WRPP and SS groups, as revealed by univariate (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.17–0.69; P = 0.003 and HR, 0.54; 95% CI, 0.31–0.95; P = 0.032, respectively) and multivariate Cox proportional hazards model (HR, 0.35; 95% CI, 0.17–0.70; P = 0.003 and HR, 0.54; 95% CI, 0.31–0.95; P = 0.032, respectively). Further, no significant differences were observed in survival outcomes between the RS group and the SS or WRPP group. Regarding the safety of WRPP, no significant differences in major intraoperative and postoperative complications were found between the three groups. Immunofluorescence analysis revealed a high percentage of CD44v6/EpCAM double-positive ovarian cancer cells in peritoneal disseminated tumors. Conclusion The present study demonstrates that WRPP significantly contributes to improved survival in patients with stage III–IV advanced ovarian cancer. WRPP could result in eradicating ovarian CSCs and disrupting the CSC niche microenvironment in the pelvic peritoneum.
- Published
- 2023
34. The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
- Author
-
Daisuke Aoki, Yoh Watanabe, Hidetaka Katabuchi, Masayuki Sekine, Nobuo Yaegashi, and Takayuki Enomoto
- Subjects
Oncology ,medicine.medical_specialty ,Bevacizumab ,medicine.medical_treatment ,Neutropenia ,Drug-related side effects and adverse reactions ,Ovarian neoplasms ,Internal medicine ,medicine ,Adverse effect ,Chemotherapy ,Proteinuria ,business.industry ,Hematology ,General Medicine ,medicine.disease ,eye diseases ,Irinotecan ,Regimen ,Surgery ,Original Article ,Drug therapy ,medicine.symptom ,Ovarian cancer ,business ,medicine.drug - Abstract
Background Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients with platinum-resistant recurrent ovarian cancer. In this retrospective analysis, we evaluated the usage patterns of bevacizumab administered for platinum-resistant recurrent ovarian cancer. Methods We obtained clinical data from 155 Japanese medical facilities between November 2013 and December 2018 via a survey. Items included the number of cases of platinum-resistant recurrent ovarian cancer treated with bevacizumab according to dosage. For regimens including bevacizumab 10 mg/kg Q2W, additional information was requested relating to concomitantly administered agents, and the efficacy and safety of the regimen. Results Of 1739 bevacizumab-containing regimens reported in 1633 patients with recurrent ovarian cancer, 264 used 10 mg/kg Q2W. The overall response rate (ORR) with this regimen was 26.1%. Response rates varied according to regimen and were particularly favorable when bevacizumab 10 mg/kg Q2W was administered with paclitaxel (ORR, 53.0%) versus liposomal doxorubicin (15.0%; P P Conclusions Bevacizumab 10 mg/kg Q2W appears efficacious for patients with recurrent ovarian cancer, with a manageable toxicity profile. Approval of this regimen is clinically desirable for Japanese patients with ovarian cancer.
- Published
- 2021
35. Angiopoietin-like protein 2 decreases peritoneal metastasis of ovarian cancer cells by suppressing anoikis resistance
- Author
-
Yuichi Oike, Kunie Obayashi, Tomomitsu Doi, Takeshi Motohara, Yuko Takeshita, Tsuyoshi Kadomatsu, Hidetaka Katabuchi, and Motoyoshi Endo
- Subjects
0301 basic medicine ,Programmed cell death ,Biophysics ,Mice, SCID ,Biochemistry ,Pathogenesis ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Downregulation and upregulation ,Mice, Inbred NOD ,Laminin ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Anoikis ,Molecular Biology ,Angiopoietin-Like Protein 2 ,Peritoneal Neoplasms ,Cell Proliferation ,Ovarian Neoplasms ,biology ,business.industry ,Cell growth ,Cell Biology ,medicine.disease ,Angiopoietin-like Proteins ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Heterografts ,Female ,business ,Ovarian cancer ,Signal Transduction - Abstract
Peritoneal metastasis is a common mode of spread of ovarian cancer. Despite therapeutic advances, some patients have intractable peritoneal metastasis. Therefore, in-depth characterization of the molecular mechanism of peritoneal metastasis is a key imperative. Angiopoietin-like protein 2 (ANGPTL2) is an inflammatory factor which activates NF-κB signaling and plays an important role in the pathogenesis of various inflammatory diseases including cancers, such as lung and breast cancer. In this study, we examined the role of ANGPTL2 in ovarian cancer peritoneal metastasis. We observed no difference of cell proliferation between ANGPTL2-expressing and control cells. In the mouse intraperitoneal xenograft model, formation of peritoneal metastasis by ANGPTL2-expressing cells was significantly decreased compared to control. In the in vitro analysis, the expressions of integrin α5β1, α6, and β4, but not those of αvβ3, α3, α4, and β1, were significantly decreased in ANGPTL2-expressing cells compared to control cells. ANGPTL2-expressing cells showed significantly inhibited adherence to laminin compared to control. In addition, we observed upregulation of anoikis (a form of programmed cell death occurring under an anchorage-independent condition) and significant decrease in the expression of Bcl-2 in ANGPTL2-expressing cells as compared to control cells. These results suggest that ANGPTL2 expression in ovarian cancer cells represses peritoneal metastasis by suppressing anoikis resistance.
- Published
- 2021
36. Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study
- Author
-
Tsukasa Baba, Tomohito Tanaka, Nobuyuki Susumu, Tsuyoshi Yamashita, Daisuke Aoki, Nobuo Yaegashi, Yoshito Terai, Ken Yamaguchi, Tomoyuki Nagai, Muneaki Shimada, Hitoshi Niikura, Hideaki Yahata, Hiroaki Kobayashi, Hidetaka Katabuchi, Shinichi Togami, and Wataru Yamagami
- Subjects
0301 basic medicine ,Cervical cancer ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Endometrial cancer ,Sentinel lymph node ,Hematology ,General Medicine ,Gynecologic oncology ,Vulvar cancer ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Clinical research ,Oncology ,Surgical oncology ,030220 oncology & carcinogenesis ,Biopsy ,medicine ,Surgery ,Radiology ,business - Abstract
Sentinel lymph node (SN) biopsy is essential for evaluating survival and minimal treatment-related morbidity associated with cervical, endometrial, and vulvar cancer in Japan. As such, our aim in this study was to evaluate the current practice pattern of using SN biopsy for cervical, endometrial, and vulvar cancer in Japan. We deployed a 47-question survey on the use of SN biopsy for gynecological cancers to 216 gynecological oncology training facilities. The survey included information on the use of SN biopsy for uterine (cervical and endometrial) and vulvar cancers; details on the type, timing, and concentration of tracers used; surgical approach used for SN biopsy; method of biopsy and pathological examination; and facilities’ experience with clinical research on SN biopsy. The response rate was 84% (181/216), with 40 facilities (22%) having experience in SN biopsy for gynecological cancers, 34 (85%) for uterine cancers, and 15 (37%) for vulvar cancers. Radioisotope, indocyanine green (ICG), and blue dyes were available for the detection of uterine cancers in 21 (52%), 25 (62%), and 19 (48%) facilities and for vulvar cancers in 9 (22%), 3 (7%), and 11 (27%) facilities, respectively. Thirty-four facilities (85%) used intraoperative frozen section procedure for diagnosis when possible, with 24 (71%) of these facilities using 2-mm specimen cuts. Diagnosis included pathological examination (85%), immunostaining (57%), and one-step nucleic acid amplification (5%). Increasing research evidence, providing insurance coverage for radioisotope tracers, and increasing the availability of training are expected to increase the use of SN biopsy in Japan.
- Published
- 2021
37. Clinical manifestations of placental mesenchymal dysplasia in Japan: A multicenter case series
- Author
-
Takashi Ohba, Masaharu Fukunaga, Yoshiki Mikami, Hidetaka Katabuchi, Ken Higashimoto, Hidenobu Soejima, Chisato Kodera, and Saori Aoki
- Subjects
medicine.medical_specialty ,Fetus ,Pregnancy ,Placenta Diseases ,Cesarean Section ,business.industry ,Obstetrics ,Placenta ,Mortality rate ,Infant, Newborn ,Pregnancy Outcome ,Obstetrics and Gynecology ,medicine.disease ,Placental Mesenchymal Dysplasia ,Human chorionic gonadotropin ,Japan ,Obstetrics and gynaecology ,Humans ,Medicine ,Female ,Fetal Demise ,Child ,business ,Adverse effect - Abstract
Aim This study aimed to evaluate the clinical features and pregnancy outcomes of placental mesenchymal dysplasia (PMD) in Japan. Methods We requested detailed clinical information and placental tissue of PMD cases in 2000-2018 from Japanese facilities with departments of obstetrics and gynecology and analyzed the pregnancy course and neonatal outcomes. Results We collected 49 cases of PMD. Of 18 patients with measured maternal serum alpha-fetoprotein (MSAFP) levels, 15 (83.3%) had elevated levels. Maternal serum human chorionic gonadotropin (MShCG) levels were transiently elevated in five (17.8%) of 28 patients. Forty-seven patients continued their pregnancies. All pregnancies were singleton and 40 (85.1%) were associated with adverse events including fetal growth restriction (FGR), threatened premature delivery, fetal demise, and hypertensive disorder of pregnancy in 34 (72.3%), 14 (29.8%), eight (17.0%), and six (12.8%) patients, respectively. Of 47 infants, there were eight stillbirths. There were 40 (85.1%) female infants, and eight (17.0%) had Beckwith-Wiedemann syndrome. Of 39 live births, 23 (59.0%) were associated with premature induction of labor or cesarean section for obstetric indications related to FGR. Eighteen (46.2%) neonates had complications. PMD-affected placentas were pathologically heterogeneous in both grossly PMD-affected and non-affected areas. Conclusions Our study included the largest number of PMD cases with detailed clinical information. PMD is a high-risk condition for both the mother and the child. Elevated MSAFP levels with normal MShCG levels indicate PMD. Conventional perinatal management of FGR in Japan might be effective in reducing the fetal mortality rate.
- Published
- 2021
38. Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan
- Author
-
Munekage Yamaguchi, Chimeddulam Erdenebaatar, Chenyan Li, Mahina Monsur, Ken-ichi Iyama, Takashi Ohba, Hironori Tashiro, Kumiko Yoshinobu, Yutaka Iwagoi, Fumitaka Saito, and Hidetaka Katabuchi
- Subjects
Adult ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,DNA Mutational Analysis ,Biology ,Pathology and Forensic Medicine ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Asian People ,medicine ,Carcinoma ,Humans ,Poly-ADP-Ribose Binding Proteins ,Molecular Biology ,Atypical Endometrial Hyperplasia ,Microdissection ,Aged ,Aged, 80 and over ,Endometrial cancer ,Cancer ,Histology ,DNA Polymerase II ,General Medicine ,Middle Aged ,medicine.disease ,Molecular medicine ,Endometrial Neoplasms ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Female ,Carcinoma, Endometrioid ,Immunostaining - Abstract
POLE-mutated endometrial cancer (EC) frequently shows high-grade endometrioid histology, which represents heterogeneity in the dualistic classification of EC. This study aimed to assess the clinicopathology and pathogenesis of POLE-mutated EC due to the scarcity of related information for Asian women. POLE variants were sequenced in tissues of Japanese women with EC. The tumor mutation burden (TMB) was assessed in tissues with a POLE variant of unknown significance. In the POLE-mutated EC tissues, the immunostaining expression of CD8, hormonal receptors, and p53 was evaluated, and the POLE variants in cancer and atypical endometrial hyperplasia (AEH) lesions were assessed by laser-capture microdissection. POLE variants were identified in five patients (3.9%) with high-grade endometrioid carcinoma among 127 patients with EC (S459F in two tissues and P441P in three tissues with a high TMB). The five cancer tissues coexisted with normal endometrium and/or AEH. Both AEH and cancer cells showed hormonal receptor positivity and harbored the same POLE mutation. Two patients showed a subclonal overexpression pattern of p53 in cancer and AEH lesions. In conclusion, POLE-mutated EC progresses through the type I pathway, even though it frequently shows high-grade endometrioid morphology. The common POLE mutation sites in EC might vary among races.
- Published
- 2021
39. Hemoglobin-induced continuous activation of macrophages in endometriotic cysts: a potential mechanism of endometriosis development and carcinogenesis
- Author
-
Yuko Imamura, Ritsuo Honda, Hidetaka Katabuchi, Yoshihiro Komohara, Maki Kusunoki, Takashi Ohba, and Yukio Fujiwara
- Subjects
Adult ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Stromal cell ,Carcinogenesis ,medicine.medical_treatment ,Endometriosis ,Antigens, Differentiation, Myelomonocytic ,Receptors, Cell Surface ,Inflammation ,Pathology and Forensic Medicine ,Proinflammatory cytokine ,Hemoglobins ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Antigens, CD ,medicine ,Humans ,Macrophage ,Molecular Biology ,Ovarian Neoplasms ,Interleukin-6 ,Chemistry ,Macrophages ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,030104 developmental biology ,Cytokine ,030220 oncology & carcinogenesis ,Cytokines ,Female ,medicine.symptom ,Ovarian cancer ,CD163 ,Adenocarcinoma, Clear Cell - Abstract
Endometriosis is a chronic inflammatory disease. Endometriotic cysts contain hemoglobin (Hb) and infiltrated macrophages, indicating that the metabolism of Hb by macrophages may play an important role in the inflammation of endometriotic cysts. In this study, we investigated the distribution of immune cells and CD163 (Hb receptor)-positive cells in the endometriotic cyst wall using immunohistochemistry. We also examined the role of macrophage activation by Hb on the pathogenesis of endometriotic cysts by measuring the cytokine concentration in the cystic fluids and macrophage-culture supernatant using ELISA. Macrophages were the most prominent immune cells observed in the endometriotic cysts and were differentially distributed in the different histological areas of the cyst wall. The localization of CD163-positive macrophages was restricted to the hemorrhagic and outer areas in the cyst wall. High concentrations of IL-6 and CCL2 were found in the cystic fluids, and inflammatory cytokines (IL-6, TNF-α, and CCL2) were secreted from macrophages on stimulation by Hb. IL-6 is a promotional factor for endometriotic stromal cells and ovarian clear cell carcinoma, the most common histological subtype of endometriosis-related ovarian cancer, hence, the continuous activation of macrophages by Hb could be a potential mechanism underlying endometriosis development and carcinogenesis.
- Published
- 2021
40. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer
- Author
-
Tokunori Ikeda, Yutaka Iwagoi, Koichi Fujimoto, Sangyoon Hwang, Takeshi Motohara, and Hidetaka Katabuchi
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Gastroenterology ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Ovarian cancer ,Internal medicine ,medicine ,Risk factor ,Stage (cooking) ,business.industry ,Hazard ratio ,Retrospective cohort study ,Hematology ,General Medicine ,medicine.disease ,Debulking ,Prognosis ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Omental metastasis ,Surgery ,Original Article ,business ,Chemoresistance - Abstract
Background Epithelial ovarian cancer has a clear predilection for the omentum as the site of metastasis; however, its contribution to clinical outcomes remains unresolved. This study aimed to evaluate the prognostic significance and efficacy of chemotherapy in the presence of omental metastasis. Methods A retrospective cohort study was performed in 56 patients with stage III–IV ovarian cancer who underwent primary debulking surgery between 2004 and 2018 at Kumamoto University Hospital. Results Thirty-six (64.3%) patients were categorized into the omental metastasis-positive group, whereas 20 (35.7%) patients were in the omental metastasis-negative group. The 5-year overall survival rates were 43.4% in the omental metastasis-positive group and 93.8% in the omental metastasis-negative group. Statistically significant differences were observed in overall survival (p = 0.002) and progression-free survival (p = 0.036) between the omental metastasis-positive and metastasis-negative groups. Notably, multivariate analysis demonstrated that the existence of omental metastasis is an independent risk factor for overall survival in patients with stage III–IV ovarian cancer (hazard ratio 8.90, 95% confidence interval 1.16–69.77; p = 0.038). Furthermore, the omental metastasis-positive group had significantly lower overall response rates to chemotherapy for recurrent disease, compared to the omental metastasis-negative group (31.6% vs. 85.7%, p = 0.026). Conclusion Our present data demonstrated that omental metastasis is closely associated with an unfavorable prognosis due to increased chemoresistance in patients with stage III–IV ovarian cancer. Elucidating the biological mechanism of omental metastasis will shed light on novel therapeutic approaches for the management of advanced ovarian cancer patients.
- Published
- 2021
41. Fertility-sparing surgery for early-stage cervical cancer: A case series study on the efficacy and feasibility of cervical conization followed by pelvic lymphadenectomy
- Author
-
Mayuko Yamamoto, Takeshi Motohara, Yutaka Iwagoi, Shingo Tayama, Hironori Tashiro, Eiji Kondoh, and Hidetaka Katabuchi
- Subjects
Adult ,Pregnancy ,Conization ,Infant, Newborn ,Obstetrics and Gynecology ,Feasibility Studies ,Fertility Preservation ,Humans ,Lymph Node Excision ,Uterine Cervical Neoplasms ,Female ,Neoplasm Staging ,Retrospective Studies - Abstract
To evaluate the oncologic and obstetric outcomes of cervical conization followed by pelvic lymphadenectomy, which is used as a fertility-sparing procedure, in reproductive-aged patients with early-stage cervical cancer.We performed a retrospective study of patients with stage IA1-IB1 cervical cancer who underwent cervical conization followed by pelvic lymphadenectomy from 2011 to 2020 at Kumamoto University Hospital.In total, eight patients underwent conization followed by pelvic lymphadenectomy. The median age of the patients was 33 (range: 28-36) years. Four (50.0%) patients were nulliparous. Seven (87.5%) patients were diagnosed with squamous cell carcinoma (87.5%) and one (12.5%) with adenocarcinoma. Five (62.5%), two (25.0%), and one (12.5%) presented with stage IA1, IA2, and IB1 disease, respectively. Five (62.5%) patients had lymphovascular space invasion (LVSI) based on the assessment of specimens obtained via conization. However, none had lymph node metastasis based on pelvic lymphadenectomy. Regarding long-term oncologic outcomes, recurrence was not observed at a median follow-up of 60 (range: 8-107) months. In addition, obstetric outcomes were consistently favorable in terms of achieving pregnancy, preterm delivery, and live birth. During the study period, two patients who actively attempted to conceive had four pregnancies, resulting in full-term deliveries, and one was on her first trimester of pregnancy.Cervical conization combined with pelvic lymphadenectomy represents a feasible conservative management for histologically well-selected patients with early-stage cervical cancer. Furthermore, an optimal histopathological evaluation of conization specimens will contribute to decision-making regarding the use of this fertility-sparing procedure.
- Published
- 2022
42. Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice
- Author
-
Koshi Mimori, Hironori Tashiro, Hidetaka Katabuchi, Kazuwa Nakao, Tak W. Mak, Miki Nishio, Akira Suzuki, Hiroshi Nishina, Tomohiko Maehama, Takehiko Sasaki, Yoko To, Akihiro Kitagawa, Junji Otani, Hiroki Hikasa, Tohru Kiyono, Yukari Aono, John P. Lydon, and Shinya Toyokuni
- Subjects
0301 basic medicine ,p53 ,Cancer Research ,Carcinogenesis ,cervical cancer ,Papillomavirus E7 Proteins ,Endogeny ,Cell Cycle Proteins ,Mice ,0302 clinical medicine ,Chromosome instability ,Papillomaviridae ,YAP1 ,Cervical cancer ,Mice, Knockout ,Hyperactivation ,Chemistry ,General Medicine ,Protein Tyrosine Phosphatases, Non-Receptor ,Hippo-YAP1 pathway ,Oncology ,oncogenic threshold ,Root Caries ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Original Article ,Signal Transduction ,HPV ,medicine.drug_class ,Cell Line ,03 medical and health sciences ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Hippo‐YAP1 pathway ,PI3K/AKT/mTOR pathway ,Adaptor Proteins, Signal Transducing ,Carcinoma ,Contact inhibition ,Epithelial Cells ,Estrogens ,YAP-Signaling Proteins ,Oncogene Proteins, Viral ,medicine.disease ,Repressor Proteins ,030104 developmental biology ,Estrogen ,Cancer research ,Phosphatidylinositol 3-Kinase ,Tumor Suppressor Protein p53 - Abstract
Cervical cancer (CC) is usually initiated by infection with high‐risk types of human papillomavirus (HPV). The HPV E6 and E7 proteins target p53 and RB, respectively, but other cellular targets likely exist. We generated uterus‐specific MOB1A/B double KO (uMob1DKO) mice, which immediately developed cervical squamous cell carcinoma in situ. Mutant cervical epithelial cells showed YAP1‐dependent hyperproliferation, altered self‐renewal, impaired contact inhibition, and chromosomal instability. p53 activation was increased in uMob1DKO cells, and additional p53 loss in uMob1DKO mice accelerated tumor invasion. In human CC, strong YAP1 activation was observed from the precancerous stage. Human cells overexpressing HPV16 E6/E7 showed inactivation of not only p53 and RB but also PTPN14, boosting YAP1 activation. Estrogen, cigarette smoke condensate, and PI3K hyperactivation all increased YAP1 activity in human cervical epithelial cells, and PTPN14 depletion along with PI3K activation or estrogen treatment further enhanced YAP1. Thus, immediate CC onset may initiate when YAP1 activity exceeds an oncogenic threshold, making Hippo‐YAP1 signaling a major CC driver., We generated uterus‐specific MOB1A/B double KO (uMob1DKO) mice, which immediately developed cervical squamous cell carcinoma in situ. Cervical cancer (CC) onset may initiate when YAP1 activity exceeds an oncogenic threshold, making Hippo‐YAP1 signaling a major CC driver. p53 activation was increased in uMob1DKO cells, and additional p53 loss in uMob1DKO mice accelerated tumor invasion.
- Published
- 2020
43. Epidemiological guideline influence on the therapeutic trend and patient outcome of uterine cervical cancer in Japan: Japan society of gynecologic oncology guideline evaluation committee project
- Author
-
Shogo Shigeta, Fumiaki Takahashi, Mikio Mikami, Daisuke Aoki, Wataru Yamagami, Masako Shida, Satoru Nagase, Nobuo Yaegashi, Takeo Shibata, Masae Ikeda, and Hidetaka Katabuchi
- Subjects
Adult ,0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Uterine Cervical Neoplasms ,Gynecologic oncology ,Hysterectomy ,Medical Oncology ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Obstetrics and gynaecology ,Epidemiology ,medicine ,Humans ,Registries ,Practice Patterns, Physicians' ,Stage (cooking) ,Societies, Medical ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Evidence-Based Medicine ,business.industry ,General surgery ,Obstetrics and Gynecology ,Guideline ,Middle Aged ,Survival Analysis ,Neoadjuvant Therapy ,Cancer registry ,Survival Rate ,Radiation therapy ,Treatment Outcome ,030104 developmental biology ,Oncology ,Chemotherapy, Adjuvant ,Gynecology ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Female ,Radiotherapy, Adjuvant ,Guideline Adherence ,business - Abstract
Objective The Japan Society of Gynecologic Oncology published its first clinical guidelines for uterine cervical cancer in 2007 which has been revised twice in 2011 and 2017. The aim of this study was to investigate the influence of the first guideline publication on the therapeutic trend and patient outcome by analyzing uterine cervical cancer cases registered to the cancer registry organized by the Japan Society of Obstetrics and Gynecology. Methods Data of uterine cervical cancer cases registered to the cancer registry from 2000 to 2012 were provided. Epidemiological and clinical trend were analyzed by the Chi-squared test with subsequent standardized residual analysis. Overall survival among the patients registered between 2004 and 2009 was analyzed using the Fine and Gray competing risk model. Results 68,707 cases were registered during the study period. A trend analysis revealed that the guideline publication may have led to a decrease in neoadjuvant chemotherapy in parallel with an increase in radiation therapy mainly in stage II and III patients undergoing primary treatment. A survival analysis indicated that the introduction of the guideline may have improved overall survival among stage III uterine cervical cancer patients, even though a significant difference was not observed in all of the cases. Conclusions This study demonstrated the potential influence of the guideline publication on the clinical trend and patient outcome. As this is the first assessment of the guideline for uterine cervical cancer in Japan, continuous evaluation is necessary to further comprehend the significance of this guideline.
- Published
- 2020
44. A National Survey of Umbilical Endometriosis in Japan
- Author
-
Yutaka Osuga, Kazuaki Neriishi, Shigeo Horie, Hisashi Narahara, Tasuku Harada, Jo Kitawaki, Kotaro Yoshimura, Tetsuya Hirata, Takayuki Enomoto, Toshiaki Tanaka, Kaori Koga, Hidetaka Katabuchi, Naoko Takazawa, Jun Nakajima, Mari Kitade, Hidekatsu Nakai, Shinya Fukuda, Masatoshi Kurihara, Ritsuo Honda, Masaki Mandai, and Fuminori Taniguchi
- Subjects
Adult ,medicine.medical_specialty ,Umbilicus (mollusc) ,Endometriosis ,Physical examination ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,Muscular Diseases ,Obstetrics and gynaecology ,Recurrence ,Surveys and Questionnaires ,medicine ,Humans ,Medical history ,Postoperative Period ,Retrospective Studies ,030219 obstetrics & reproductive medicine ,Umbilicus ,medicine.diagnostic_test ,business.industry ,Obstetrics and Gynecology ,Middle Aged ,medicine.disease ,Surgery ,Plastic surgery ,Treatment Outcome ,Dienogest ,chemistry ,030220 oncology & carcinogenesis ,Hormonal therapy ,Female ,business - Abstract
Study Objective To identify the clinical presentation, diagnostic evaluation, operative or medical management, and postoperative recurrence of umbilical endometriosis. Design A retrospective national survey. Setting Obstetrics and Gynecology and Plastic Surgery Departments at a teaching hospital in Japan. Patients Patients with umbilical endometriosis or malignant transformation. Interventions A national survey was conducted to identify and evaluate cases of umbilical endometriosis or malignant transformation documented between 2006 and 2016. Measurements and Main Results The following were evaluated for each patient: age at diagnosis, body mass index, medical history, presence of extragenital endometriosis, surgical history, symptoms, imaging modalities, surgical therapy, hormonal therapy, follow-up period, postoperative recurrence, and time to recurrence. Ninety-six patients were identified with pathologically diagnosed benign umbilical endometriosis. The patients frequently had swelling (86.5%), pain (81.3%), or bleeding (44.8%) in the umbilicus. Sensitivity was 87.1% for physical examination, 76.5% for transabdominal ultrasonography, 75.6% for computed tomography, and 81.8% for magnetic resonance imaging. The cumulative recurrence rate was 1.34% at 6 months, 6.35% at 12 months, and 6.35% at 60 months after surgery. Importantly, there was no recurrence after wide resection including of the peritoneum (0 of 37 cases). The efficacy of dienogest (an oral progestin), gonadotropin-releasing hormone agonists, and oral contraceptives was 91.7%, 81.8%, and 57.1%, respectively. Finally, 2 cases of malignant transformation were identified. Conclusion There was a low recurrence rate following surgery, and hormonal treatment is an option, although the current findings suggest surgical therapy as the first choice of treatment for umbilical endometriosis.
- Published
- 2020
45. Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
- Author
-
Yusuke, Kobayashi, Kenta, Masuda, Akira, Hiraswa, Kazuhiro, Takehara, Hitoshi, Tsuda, Yoh, Watanabe, Katsutoshi, Oda, Satoru, Nagase, Masaki, Mandai, Aikou, Okamoto, Nobuo, Yaegashi, Mikio, Mikami, Takayuki, Enomoto, Daisuke, Aoki, and Hidetaka, Katabuchi
- Subjects
Oncologists ,Ovarian Neoplasms ,Japan ,Oncology ,Surveys and Questionnaires ,Humans ,Obstetrics and Gynecology ,Breast Neoplasms ,Female ,General Medicine ,Carcinoma, Ovarian Epithelial - Abstract
The practices pertaining to hereditary breast and ovarian cancer (HBOC) in Japan have been rapidly changing owing to the clinical development of poly(ADP-ribose) polymerase inhibitors, the increasing availability of companion diagnostics, and the broadened insurance coverage of HBOC management from April 2020. A questionnaire of gynecologic oncologists was conducted to understand the current status and to promote the widespread standardization of future HBOC management.A Google Form questionnaire was administered to the members of the Japan Society of Gynecologic Oncology. The survey consisted of 25 questions in 4 categories: respondent demographics, HBOC management experience, insurance coverage of HBOC management, and educational opportunities related to HBOC.A total of 666 valid responses were received. Regarding the prevalence of HBOC practice, the majority of physicians responded in the negative and required human resources, information sharing and educational opportunities, and expanded insurance coverage to adopt and improve HBOC practice. Most physicians were not satisfied with the educational opportunities provided so far, and further expansion was desired. They remarked on the psychological burdens of many HBOC managements. Physicians reported these burdens could be alleviated by securing sufficient time to engage in HBOC management, creating easy-to-understand explanatory material for patients, collaboration with specialists in genetic medicine, and educational opportunities.Gynecologic oncologists in Japan are struggling to deal with psychological burdens in HBOC practice. To promote the clinical practice of HBOC management, there is an urgent need to strengthen human resources and improve educational opportunities, and expand insurance coverage for HBOC management.
- Published
- 2022
46. Reduction in HPV16/18 prevalence among young women with high‐grade cervical lesions following the Japanese HPV vaccination program
- Author
-
Koji, Matsumoto, Nobuo, Yaegashi, Takashi, Iwata, Kasumi, Yamamoto, Yoichi, Aoki, Masao, Okadome, Kimio, Ushijima, Shoji, Kamiura, Kazuhiro, Takehara, Koji, Horie, Nobutaka, Tasaka, Kenzo, Sonoda, Yuji, Takei, Katsuyuki, Konnai, Hidetaka, Katabuchi, Keiichiro, Nakamura, Mitsuya, Ishikawa, Hidemichi, Watari, Hiroyuki, Yoshida, Noriomi, Matsumura, Hidekatsu, Nakai, Shogo, Shigeta, Fumiaki, Takahashi, Kiichiro, Noda, and Hiroyuki, Yoshikawa
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Papillomavirus Vaccines ,Prospective Studies ,Child ,Prospective cohort study ,Adverse effect ,Letter to the Editor ,Cervical cancer ,Human papillomavirus 16 ,Human papillomavirus 18 ,business.industry ,Incidence (epidemiology) ,Adenocarcinoma in situ ,Vaccination ,Hpv vaccination ,General Medicine ,Uterine Cervical Dysplasia ,medicine.disease ,female genital diseases and pregnancy complications ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Female ,business - Abstract
The Japanese government began a human papillomavirus (HPV) vaccination program for girls aged 12‐16 years in 2010 but withdrew its recommendation in 2013 because of potential adverse effects, leading to drastically reduced vaccination uptake. To evaluate population‐level effects of HPV vaccination, women younger than 40 years of age newly diagnosed with cervical intraepithelial neoplasia grade 1‐3 (CIN1‐3), adenocarcinoma in situ (AIS), or invasive cervical cancer (ICC) have been registered at 21 participating institutes each year since 2012. A total of 7709 women were registered during 2012‐2017, of which 5045 were HPV genotyped. Declining trends in prevalence of vaccine types HPV16 and HPV18 during a 6‐year period were observed in CIN1 (50.0% to 0.0%, P trend
- Published
- 2019
47. Aberrant hypomethylation at imprinted differentially methylated regions is involved in biparental placental mesenchymal dysplasia
- Author
-
Saori Aoki, Ken Higashimoto, Hidenori Hidaka, Yasufumi Ohtsuka, Shigehisa Aoki, Hiroyuki Mishima, Koh-ichiro Yoshiura, Kazuhiko Nakabayashi, Kenichiro Hata, Hitomi Yatsuki, Satoshi Hara, Takashi Ohba, Hidetaka Katabuchi, and Hidenobu Soejima
- Subjects
Genomic Imprinting ,Beckwith-Wiedemann Syndrome ,Pregnancy ,Placenta ,Uterine Neoplasms ,Genetics ,Humans ,Female ,Hydatidiform Mole ,DNA Methylation ,Molecular Biology ,Genetics (clinical) ,Developmental Biology - Abstract
Background Placental mesenchymal dysplasia (PMD) is a morphological abnormality resembling partial hydatidiform moles. It is often associated with androgenetic/biparental mosaicism (ABM) and complicated by Beckwith–Wiedemann syndrome (BWS), an imprinting disorder. These phenomena suggest an association between PMD and aberrant genomic imprinting, particularly of CDKN1C and IGF2. The existence of another type of PMD containing the biparental genome has been reported. However, the frequency and etiology of biparental PMD are not yet fully understood. Results We examined 44 placental specimens from 26 patients with PMD: 19 of these were macroscopically normal and 25 exhibited macroscopic PMD. Genotyping by DNA microarray or short tandem repeat analysis revealed that approximately 35% of the macroscopic PMD specimens could be classified as biparental, while the remainder were ABM. We performed a DNA methylation analysis using bisulfite pyrosequencing of 15 placenta-specific imprinted differentially methylated regions (DMRs) and 36 ubiquitous imprinted DMRs. As expected, most DMRs in the macroscopic PMD specimens with ABM exhibited the paternal epigenotype. Importantly, the biparental macroscopic PMD specimens exhibited frequent aberrant hypomethylation at seven of the placenta-specific DMRs. Allelic expression analysis using single-nucleotide polymorphisms revealed that five imprinted genes associated with these aberrantly hypomethylated DMRs were biallelically expressed. Frequent aberrant hypomethylation was observed at five ubiquitous DMRs, including GRB10 but not ICR2 or ICR1, which regulate the expression of CDKN1C and IGF2, respectively. Whole-exome sequencing performed on four biparental macroscopic PMD specimens did not reveal any pathological genetic abnormalities. Clinical and molecular analyses of babies born from pregnancies with PMD revealed four cases with BWS, each exhibiting different molecular characteristics, and those between BWS and PMD specimens were not always the same. Conclusion These data clarify the prevalence of biparental PMD and ABM-PMD and strongly implicate hypomethylation of DMRs in the pathogenesis of biparental PMD, particularly placenta-specific DMRs and the ubiquitous GRB10, but not ICR2 or ICR1. Aberrant hypomethylation of DMRs was partial, indicating that it occurs after fertilization. PMD is an imprinting disorder, and it may be a missing link between imprinting disorders and placental disorders incompatible with life, such as complete hydatidiform moles and partial hydatidiform moles.
- Published
- 2021
48. Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study
- Author
-
Nobuo Yaegashi, Mikio Mikami, Daisuke Aoki, Hidetaka Katabuchi, Satoru Nagase, Takayuki Enomoto, Wataru Yamagami, Hiroko Machida, Koji Matsuo, Koji Oba, Masaki Mandai, and Aikou Okamoto
- Subjects
medicine.medical_specialty ,Survival ,Genital Neoplasms, Female ,Uterine Cervical Neoplasms ,Cervical Cancer ,Outcomes Research ,Endometrial Cancer ,Ovarian tumor ,Japan ,Obstetrics and gynaecology ,medicine ,Humans ,Registries ,Retrospective Studies ,Cervical cancer ,business.industry ,Obstetrics ,Proportional hazards model ,Endometrial cancer ,Hazard ratio ,Obstetrics and Gynecology ,Retrospective cohort study ,General Medicine ,medicine.disease ,Hospitals ,Ovarian Cancer ,Editorial ,Oncology ,Female ,Original Article ,Hospital, high-volume ,Ovarian cancer ,business - Abstract
Objective Associations between hospital treatment volume and survival outcomes for women with 3 types of gynecologic malignancies, and the trends and contributing factors for high-volume centers were examined. Methods The Japan Society of Obstetrics and Gynecology tumor registry databased retrospective study examined 206,845 women with 80,741, 73,647, and 52,457 of endometrial, cervical, and ovarian tumor, respectively, who underwent primary treatment in Japan between 2004 and 2015. Associations between the annual treatment volume and overall survival (OS) for each tumor type were examined using a multivariable Cox proportional hazards model with restricted cubic splines. Institutions were categorized into 3 groups (low-, moderate-, and high-volume centers) based on hazard risks. Results Hazard ratio (HR) for OS each the 3 tumors decreased with hospital treatment volume. The cut-off points of treatment volume were defined for high- (≥50, ≥51, and ≥27), moderate- (20–49, 20–50, and 17–26), and low-volume centers (≤19, ≤19, and ≤16) by cases/year for endometrial, cervical, and ovarian tumors, respectively. Multivariate analysis revealed younger age, rare tumor histology, and initial surgical management as contributing factors for women at high-volume centers (all, p, Synopsis For women with gynecologic malignancy, hospital treatment volume had an impact on survival outcome. The practice pattern shifted with scattering of patients and treatments at high-volume centers were decreasing. High-volume centers in Japan were associated with improved overall survival of gynecologic malignancies.
- Published
- 2021
49. Impact of COVID-19 on cervical cancer screening in Japan: A survey of population-based screening in urban Japan by the Japan Society of Gynecologic Oncology
- Author
-
Yuya, Nogami, Takeshi, Makabe, Hiroaki, Komatsu, Kei, Kawana, Aikou, Okamoto, Mikio, Mikami, and Hidetaka, Katabuchi
- Subjects
Japan ,SARS-CoV-2 ,Surveys and Questionnaires ,Obstetrics and Gynecology ,COVID-19 ,Humans ,Uterine Cervical Neoplasms ,Female ,Early Detection of Cancer - Abstract
To assess the impact of COVID-19 on cervical cancer screening.The Japanese Society of Gynecologic Oncology launched COVID-19 Task Force surveyed the municipalities in urban areas of Japan. Questionnaires were sent to 20 ordinance-designated cities and 23 wards of Tokyo metropolitan area in Japan via telephone and mail in January 2021. An additional survey was conducted in March and April 2021, counted the monthly checkups in 2020 and, as a control data, the number of monthly checkups in 2019. "The State of Emergency" between April 7 and May 25, 2020, included 13 prefectures. The data collected in this research involved the number of screenings only. The chi-square test was performed for statistical analysis.The number of cancer screenings from March to August, with May being the month with the lowest number of screenings, was less than 50% of that in the previous year. In particular, the drop in the number of cancer screenings in the "Prefectures operating under special safety precautions" was remarkable and significantly lower than that in other Prefectures. However, after August, the number recovered to the usual level, despite the second wave of the pandemic occurring nationwide. The initial "the State of Emergency" caused a significant decrease in the number of people receiving population-based screenings, but the recovery has been remarkable, and the total number is expected to be the same as in previous years.The initial "the State of Emergency" caused a significant decrease in the number of people receiving population-based screenings.
- Published
- 2021
50. Aberrant hypomethylation at imprinted differentially methylated regions is involved in biparental placental mesenchymal dysplasia
- Author
-
Hidenobu Soejima, Saori Aoki, Ken Higashimoto, Hiroyuki Mishima, Koh-ichiro Yoshiura, Kazuhiko Nakabayashi, Kenichiro Hata, Satoshi Hara, Takashi Ohba, and Hidetaka Katabuchi
- Subjects
Reproductive Medicine ,Obstetrics and Gynecology ,Developmental Biology - Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.